BioCardia (BCDA) Receivables - Other (2011 - 2021)
BioCardia's (BCDA) quarterly Receivables - Other came in at $562000.0 in Q4 2021, down 9.06% year-over-year from $618000.0 in Q4 2020, and little changed quarter-over-quarter from $562000.0 in Q3 2021.
Powered by 
Analysis
BioCardia (BCDA) Receivables - Other (2011 - 2021) Analysis & Trends
BioCardia (BCDA) has reported Receivables - Other for 3 consecutive years, with $562000.0 the latest figure, recorded in Q4 2021.
- On a quarterly basis, Receivables - Other fell 9.06% year-over-year to $562000.0 in Q4 2021; TTM through Dec 2021 was $562000.0, a 9.06% decrease from a year earlier, with the FY2021 full-year figure at $562000.0, down 9.06% from the prior year.
- Receivables - Other was $562000.0 for Q4 2021 at BioCardia, roughly flat from $562000.0 in the prior quarter.
- Over five years, Receivables - Other peaked at $762000.0 in Q3 2020 and troughed at $562000.0 in Q3 2021.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Krystal Biotech | 10.60 Bn | 9.76 Bn | 112.79 Mn |
| 2 | CRISPR Therapeutics AG | 5.39 Bn | 5.39 Bn | - |
| 3 | Iovance Biotherapeutics | 3.98 Bn | 3.68 Bn | 55.72 Mn |
| 4 | Legend Biotech | 3.97 Bn | 3.00 Bn | 251.50 Mn |
| 5 | uniQure | 3.09 Bn | 3.09 Bn | 5.49 Mn |
| 6 | Beam Therapeutics | 3.06 Bn | 3.06 Bn | - |
| 7 | Precigen | 2.54 Bn | 2.54 Bn | 52.17 Mn |
| 8 | Sarepta Therapeutics | 2.38 Bn | 1.58 Bn | 251.87 Mn |
| 9 | Vericel | 2.06 Bn | 1.89 Bn | 56.40 Mn |
| 10 | BioCardia | 13.06 Mn | 8.94 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2021 | 562,000.00 |
| Sep 30, 2021 | 562,000.00 |
| Mar 31, 2021 | 623,000.00 |
| Dec 31, 2020 | 618,000.00 |
| Sep 30, 2020 | 762,000.00 |
| Sep 30, 2011 | 171,000.00 |